OXIS International, Inc. (OTCMKTS:OXIS) Streaks to New Highs

473

We began tracking OXIS International, Inc. (OTCMKTS:OXIS) this summer at the end of June, and shortly thereafter witnessed a low of .0152, but ever since then the stock has gone on a fantastic run, and pushed to a new high of .085 to start off the week. That’s a summer season swing of 459%

Even as measured from the .028 low we observed on the day of our most recent article on the stock (Aug 2nd) the new high represents a move of 203.5%

Toward the end of last week it was reported that OXIS International, Inc. (OTCMKTS:OXIS)Executive Chairman, Anthony J. Cataldo and Chief Executive Officer, Dr. Kathleen Clarence-Smith will discuss the company’s promising oncology and central nervous system drugs during a presentation in September at the Rodman & Renshaw investor conference in New York.

GT Biopharma is in the process of completing the merger of Oxis International Inc. and Georgetown Translational Pharmaceuticals Inc. (GTP). The merger combines Oxis’ promising oncology drugs with GTP’s central nervous system drugs and GTP’s leadership team, which includes incoming CEO Dr. Clarence-Smith, an experienced pharmaceutical industry executive. The deal is expected to close before September 30.

 

More than 300 companies are expected to present at the conference from September 10 to September 12 at the Lotte New York Palace Hotel.

“We are excited that this will be the first time that Dr. Kathleen Clarence-Smith and I will speak publicly about our new company and our combined assets,” said Mr. Cataldo, who served many years as Chief Executive Officer of Oxis prior to the merger. “We look forward to sharing news about developments from both companies and the benefits that our combined company will create.”

Prior to founding GTP, Dr. Clarence-Smith co-founded Chase Pharmaceuticals Corporation in Washington D.C. and served as Chairman of the company’s Board from 2008 to 2014. Chase Pharmaceuticals was acquired by Allergan, PLC (AGN) in 2016 in a deal that, with milestones, could reach $1 billion.

Dr. Clarence-Smith also held executive management positions with Sanofi, Roche, Otsuka Pharmaceutical and Prestwick Scientific Capital. She is co-founder and a managing member of KM Pharmaceutical Consulting in Washington, D.C.

Additionally, GT Biopharma, Inc’s management team will be joined by a new Chief Medical Officer (CMO) formerly Vice President and Chief Medical Officer and Medical Director of Oncology Clinical R&D of Pfizer, Inc. (PFE). (Source: OTC Disclosure & News Service)

This latest news comes just a week removed from another announcement revealing that four patients have been enrolled in the company’s Food and Drug Administration-approved (FDA) Phase 2 clinical trial of its promising cancer therapy, OXS-1550.

Oxis Biotech, a wholly owned subsidiary of GT Biopharma, owns the worldwide rights to commercialize OXS-1550. The targeted immuno-oncology company is focused on novel antibody constructs that provide alternative treatments to cancer patients for whom existing therapies have failed.

The Phase 2 clinical trial is being conducted with Oxis’ partner, the University of Minnesota’s Masonic Cancer Center. Earlier this year, researchers at the University of Minnesota completed a Phase 1 trial of OXS-1550 to determine the safe and effective dose of the drug. The Phase 2 portion of the trial began in April and a total of 12 patients are expected to participate. (Source: OTC Disclosure & News Service)

Between the promising study and the mega-run the stock has put up on the chart, we’re definitely going to want to continue our coverage of OXIS moving forward. Stay locked to Street Register for updates, and we’ll deliver important developments on OXIS as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!

Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in OXIS stock, short or long

 

LEAVE A REPLY